Study on Memantine for Patients with Cirrhosis and Liver Cancer

Inclusion Criteria

• Must be 18 years or older.
• Have a new diagnosis of liver cancer that has not been treated before, confirmed by tests or scans, with at least one measurable tumor.
• Cancer must be advanced and cannot be removed by surgery, as determined by a team of cancer specialists.
• Have a specific level of liver function impairment (Child-Pugh score of B7 or higher) and not be suitable for aggressive treatment.
• Be in relatively good health, with a performance status score between 0 and 2.
• Have adequate blood counts and organ function.
• Agree to use effective birth control if sexually active, as memantine can harm an unborn baby. Women must have a negative pregnancy test before starting the study.
• Be able to understand and sign a consent form.
• Open to all adults regardless of race, ethnicity, or sexual orientation.

Exclusion Criteria

• Have a less severe form of liver cirrhosis (Child-Pugh A).
• Be pregnant or breastfeeding.
• Have other illnesses or conditions that could interfere with the study or pose additional risks.
• Have a life-threatening illness.
• Be unlikely to follow the study requirements.
• Be participating in another clinical trial.
• Have active tuberculosis.
• Have significant heart disease or recent heart attack or stroke.
• Have certain types of liver cancer (fibrolamellar, sarcomatoid, or mixed cholangiocarcinoma and liver cancer).
• Have uncontrolled pain related to the tumor.
• Have had major surgery or injury within the last 28 days.
• Have untreated or worsening cancer spread to the brain.
• Be receiving other cancer treatments, except for radiation to relieve symptoms.